 While polymorphisms of the D4 and D3 receptor have been implicated in depression, associations have not been consistently replicated.Similar inconsistency has been found in postmortem studies, but various dopamine receptor agonists show promise in treating MDD.There is some evidence that there is decreased nigrostriatal pathway activity in people with melancholic depression (psychomotor retardation).